Altre lingue Organon & Co.

Azioni

OGN

US68622V1061

Mercato chiuso - Nyse Altri mercati azionari 22:00:02 24/04/2024			Variaz. 5gg	Var. 1 gen.
18,71 ^USD	+1,03%		+4,70%	+29,75%

09/04	ORGANON & CO. : per Morgan Stanley il titolo è Neutral	ZM
08/04	Il biosimilare di denosumab HLX14 di Shanghai Henlius Biotech raggiunge l'endpoint	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios	08/04
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte	08/04
L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires	08/04
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	08/04
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024	08/04
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints	08/04
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	20/03
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health	08/03
Philips : une nouvelle directrice financière en octobre	28/02
New York attorney general urges stronger safety warning on asthma drug Singulair	23/02
Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs, Replacing HUMIRA on Its National Formulary	21/02
Organon's Hadlima Chosen by VA as Substitute for Humira	20/02
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary	20/02
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02
Organon Launches U.S. Grant Programs and Listening Tour as Part of "Her Plan Is Her Power," Reaching High-Need Communities To Help Reduce Unplanned Pregnancies	20/02
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	15/02
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	15/02
Organon: Q4 Earnings Snapshot	15/02
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Organon & Co.

Azioni

OGN

US68622V1061

Altre lingue

Filtri